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Globally, more than 500,000 new 
cases of cervical cancer are diagnosed 
annually with over 80% of these cases 
in developing countries1. In developed 
countries, the incidence and 
prevalence of cervical cancer has 
been declining due to accessible 
organized cervical cancer screening 
using conventional cytology (Pap 
smear) and treatment of precancers. 
Available published data shows that 
cervical cancer mortality has 
decreased by 70 % over the past five 
decades in the United States following 
the introduction of pap smear.2 
Similarly, in Finland, the incidence of 
cervical cancer has reduced by more 
than 80% since the introduction of an 
organized cytology based screening 
programme.3 In sub-Saharan African, 
it accounts for 22.2% of all cancers in 
women and it is also the most common 
cause of cancer death among 
women.4 Also, about 60-75% of 
women in sub-Saharan Africa who 
develop cervical cancer live in rural 
areas and have no access to cervical 
screening.5 Despite the successes 
recorded in cervical cancer control in 
developed countries, this scenario has 
not been replicated in developing 
countries. Perhaps, the peculiar 
circumstances in these under 
resourced settings with widespread 
poverty, weak health infrastructure and 
other basic challenges are important 
obstacles that have made organized 
cervical cancer screening based on 
Pap smear largely unsuccessful. 
Therefore, there may be a need to re-
evaluate the use of cytology as the 
primary tool for cervical cancer 
screening in limited resource settings.  
The population of women in Nigeria 
over 15 years who are potentially at 
risk of developing cervical cancer is 
estimated at 40.43 million persons.6 
Also, current estimates indicate that 
every year approximately 10,000 
women are diagnosed with cervical 
cancer and 8000 die from the disease 
while about 23.7% of women in the 
general population are estimated to 
harbor cervical HPV (the causative 
agent for cervical cancer) infection at a 
given time.6 The disparity between 
cervical cancer morbidity and mortality 
in the developed nations and Nigeria 
may probably be due to lack of 
organized accessible cervical cancer 
screening, high level of competing 
health needs, wide spread poverty and 
inappropriate health seeking 
behaviour. 
Cervical cancer prevention 
worldwide is based on screening 
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women using conventional cytology 
(Pap smear). Pap smear screening 
was developed in the 1930s and 
named after the inventor, Dr. George 
Papanicolaou. Pap smear programs, 
also known as cytological screening 
programs, have achieved impressive 
results in reducing cervical cancer 
incidence and mortality in some 
developed countries. Indeed, it has 
been estimated that cervical cancer 
incidence can be reduced by as much 
as 90 percent where screening quality 
and coverage are high.7 For example, 
in Finland, a national cervical cancer 
screening program that was launched 
in 1963 decreased the cervical cancer 
rate to 5.5 cases per 100,000 women, 
a rate that is among the lowest in the 
world.8 In contrast to developing 
countries, where about 80 percent of 
all new cases exist, it has been 
estimated that only five percent of 
women have had a Pap smear in the 
last five years.9   
Pap smear is a multistage process 
that involves sampling cells from the 
transitional zone of the cervix using 
either a wooden spatula or a brush. 
The cells are smeared on a glass slide 
and appropriately fixed while the slide 
is sent to a trained cytopathologist for 
review and detection of abnormality. 
This multistage process can take 
several weeks before the results are 
available to the client, although in well-
organized programs results can be 
available sooner.  A promising 
cytology based method is the Liquid 
based cytology (LBC) which is more 
sensitive (94.4%) than pap smears 10 
and has a potential to reduce the 
number of visits by clients for 
unsatisfactory smears and in addition 
provide specimen for HPV DNA 
testing. LBC is however more 
expensive than the Pap smear and 
requires technical laboratory support 
for successful implementation. This 
drawback is an important challenge to 
its widespread use in limited resource 
settings. 
Published data revealed varying 
degrees of sensitivity and specificity 
for Pap smear when conducted at 
different settings. In a study conducted 
at Kenya, pap smear had a sensitivity 
and specificity of 83% and 94.6% 
respectively, 10 in another study in 
India, pap smear had a sensitivity and 
specificity of 53.7% and 50% 
respectively,11 while in another study 
carried out in rural Peru, pap smear 
had a sensitivity and specificity of 26% 
and 99% respectively.12 Therefore, a 
particular client may require more than 
one smear for a reliable diagnosis to 
be made before planning for treatment 
of premalignant lesions detected. This 
may reduce compliance of clients to 
screening programs especially as 
premalignant lesions are asymptomatic. 
Even when screening coverage is 
high, if premalignant lesions are not 
detected and properly managed, the 
overall objective of reducing new 
cases of cervical cancer may not be 
readily achievable. In Nigeria; a 
developing country, conventional Pap 
smear screening may not therefore be 
the ideal technology of choice for a 
successful population based screening 
program.  
Recently, Visual Inspection 
Approach (VIA) using either 3-5% 
acetic acid or Lugol’s Iodine solution to 
stain the cervix has been used for 
cervical cancer screening programs 
especially in developing countries. 
Visual inspection with acetic acid is a 
simple painless screening procedure 
that takes about 5minutes to perform. 
The Client is counseled on the 
procedure and an informed consent 
taken. With the client placed in a 
lithotomy position, a pelvic 
examination is done, and a 3-5% 
acetic acid or Vinegar solution is 
applied with a swab on stick within the 
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transitional zone of her uterine cervix 
and result read after about a minute. 
The result could be normal if there is 
no color change or positive if a dense 
white color is noted within the area of 
application of the 3-5% acetic acid. 
VIA have specificity and a sensitivity of 
73.3% and 80.0%respectively. 10 This 
is comparable to published data on 
conventional pap smears. The benefit 
of the visual approach over Pap smear 
is that the results are immediate and 
as a result treatment could be offered 
on the spot for precancerous lesions. 
The Single Visit Approach (SVA) 
involves offering cervical screening 
with Visual inspection method using 
either 3-5% acetic acid or Lugols 
iodine and treatment offered to clients 
with noted precancerous lesions. The 
treatment offered an abnormal VIA 
screening is either an excision 
treatment or an ablative method using 
cryotherapy. Cryotherapy is a painless 
procedure which takes about 15 -20 
minutes to perform; it is relatively 
inexpensive compared to other 
treatment modalities and is effective 
for premalignant lesions.  
VIA can be performed by lower 
cadres of health personnel, does not 
require high tech expensive 
technology and infrastructure to 
perform, is very affordable, and 
provides almost the same result as the 
pap smear used in developed nations. 
In addition, it is has been observed in 
some studies that VIA reduces the 
percentage of women lost to follow up 
and the need for multiple visits to the 
health facility. 13  
However VIA is best suited for 
women whose transformation zone is 
still visible in the ecto-cervix during 
speculum examination. Hence, its use 
may be limited in screening 
postmenopausal women. 
Recently, studies have 
demonstrated that HPV DNA test 
results are more sensitive than Pap 
smear in detecting high grade 
dysplasia in older women.14, 15 The 
direct detection of HPV in cervical 
specimen may therefore offer an 
alternative or complement to 
population based cytological 
screening. The advantages of HPV 
DNA testing over cytology are that it 
does not require the same level of 
technical expertise as cervical 
cytology; it is amenable to large scale 
population based screening and 
identifies women with current disease 
and those at risk of developing the 
disease over the next 2-3 years. 
Currently, HPV DNA testing is 
comparatively more expensive and 
may not be readily available or 
accessible in limited resource settings. 
It is expected that the cost of 
administering HPV DNA testing will 
reduce in future and the need for its 
use in limited resource settings in 
cervical cancer screening programmes 
may become more compelling.  
In conclusion,because of the 
challenges associated with ensuring 
high quality cytology based services in 
limited resource setting, and with the 
high cost of conducting HPV DNA 
screening, an organized VIA approach 
may be a useful alternative to the 
conventional cytology and HPV DNA 
testing in screening for cervical cancer. 
It offers a comparatively cheaper 
screening platform with minimal 
manpower requirements. In addition, 
the problem of ‘loss to follow up’ 
associated with cytology based 
screening can be avoided with a single 
visit ‘screen and treat’ model thereby 
offering treatment for screen positive 
persons. However, there may be still 
be a role for cytology based screening 
in focal communities where there is 
availability of the required man power 
and a motivated client base. This 
approach may be the most appropriate 
in limited resource settings in the short 
to medium term pending the increased 
accessibility and affordability of newer 
techniques such as HPV DNA testing. 
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